Merck & Co., Inc. (MRK) rises after reporting stronger-than-expected third-quarter results, led by $18.1 billion in sales, $2.04 GAAP EPS, and standout growth from KEYTRUDA and WINREVAIR. Investors also reacted to encouraging oncology data and a constructive full-year outlook, though valuation remains elevated.
Merck & Co., Inc. (MRK) rose 5.3% after its third-quarter 2026 earnings report showed $18.1 billion in sales, $2.04 in GAAP EPS, and stronger-than-expected operating momentum. The gain was driven by KEYTRUDA’s continued growth, a 93% jump in WINREVAIR sales, and encouraging oncology data from ESMO 2026, all of which reinforced Merck’s growth outlook for investors. The stock’s move is bullish, but the elevated valuation means the market is now demanding continued execution.
Merck & Co., Inc. (MRK) rises 5.32% to $148.425 at 10:00 a.m. ET on October 29, 2026, after its third-quarter results delivered $18.1B in sales and $2.04 in GAAP EPS. The move reflects a clear earnings-driven repricing, although the latest share-volume reading does not confirm above-average turnover: 1.29 million shares traded early while relative volume stood at 0.2x its 200-day average.
Key Takeaways
MRK gained 5.32% after Merck reported strong third-quarter sales, earnings, and a constructive full-year outlook.
The main catalyst was Merck’s October 29 Q3 2026 earnings release, supported by encouraging oncology data from ESMO 2026.
KEYTRUDA sales grew 6%, while WINREVAIR sales jumped 93%, giving investors evidence of both franchise durability and product diversification.
The move is bullish, but the 0.2x relative-volume reading argues against describing the stock as trading above its normal share volume at the 10:00 a.m. snapshot.
Investors now face a familiar trade-off: strong operating momentum versus a market snapshot showing a 111.85 P/E.
The specific catalyst is Merck’s third-quarter 2026 earnings update, published at 6:30 a.m. EDT on October 29. The company reported , up 5% year over year and 4% excluding foreign-exchange effects. GAAP EPS reached $2.04, while non-GAAP EPS came in at $2.49.
Both EPS figures included a $0.12 per-share charge tied to a global license agreement with SciBrunch. Even with that charge, the October 29 earnings headline said Merck’s results topped Wall Street views. That combination gives the market a concrete reason to reprice MRK rather than treat the gain as a broad healthcare-sector move.
The options tape adds another layer. Calls represented 66% of total MRK contracts in one live snapshot, with the $145 call expiring October 30 as the most active contract. That positioning fits an earnings setup where traders expected a sharp move, although options activity does not prove the cause of the stock gain.
The volume detail deserves precision. MRK traded 1.29 million shares early in the session, but the separate relative-volume reading was 0.2x the 200-day average. Therefore, the earnings catalyst is well supported, while the claim of above-average share volume is not supported by the latest normalized measure.
How Merck’s Q3 2026 Results Strengthen the MRK Stock Story
Merck’s product mix explains why investors responded positively. KEYTRUDA and KEYTRUDA QLEX generated $8.6B in third-quarter sales, up 6% year over year. KEYTRUDA QLEX contributed $830M. For a large pharmaceutical company, continued growth from a flagship oncology franchise supports current revenue while the pipeline develops.
WINREVAIR supplied the quarter’s strongest growth signal. Sales reached $694M, up 93% year over year. That result matters because it gives Merck a second visible growth engine beyond its dominant oncology franchise. Animal health sales also reached $1.7B, up 4% year over year, adding stability to the broader business.
Merck also presented first-time pivotal data from Phase 3 oncology trials at ESMO 2026. On October 26, the company reported that sacituzumab tirumotecan reduced the risk of death by 32% and the risk of disease progression or death by 41% versus chemotherapy in certain advanced or recurrent endometrial cancer patients. KEYTRUDA monotherapy reduced the risk of disease progression or death by 43% in certain dMMR endometrial cancer patients.
Those results support Merck’s claim that its late-stage pipeline is becoming more clinically de-risked. In plain English, the company is showing more ways to extend its oncology platform beyond a single product. That evidence gives the earnings report strategic weight, not just a one-quarter revenue boost.
MRK Valuation, Competitive Position, and Investor Risk
MRK’s financial profile combines scale with a demanding valuation snapshot. Merck’s market capitalization stands at $366.19B, while the listed EPS is $1.26 and the P/E is 111.8492. That multiple places a high bar under the stock, even after the strong quarter. A 2.34% dividend yield offers income, while a beta of 0.222 points to historically lower sensitivity than many growth stocks.
The competitive case rests on the breadth of Merck’s portfolio. KEYTRUDA remains the anchor, while WINREVAIR, vaccines, animal health products, and additional medicines spread revenue across several businesses. The company’s worldwide portfolio includes Gardasil, Capvaxive, Welireg, Januvia, and other established brands. That breadth does not remove product and patent risks, but it gives MRK more operating supports than a single-asset biotech.
MRK now trades at $148.425, below its 52-week high of $155.9991 and well above its 52-week low of $79.6706. Recent analyst actions also show a constructive backdrop. Barclays raised its Merck price target from $150 to $180 on October 26, while the analyst consensus target stands at $159.61. The consensus rating is Buy, based on 26 buy ratings, 11 holds, and one sell rating.
Merck’s 2026 Outlook and the Actionable MRK Investor View
Merck anticipates full-year 2026 worldwide sales of $66.8B to $67.3B. That range gives investors a clear operating benchmark after the third-quarter update. The company’s 5% quarterly sales growth, 93% WINREVAIR growth, and continued KEYTRUDA expansion support the revenue outlook with reported results rather than broad promises.
The actionable read is to separate the catalyst from the valuation. Earnings strength and ESMO data support the bullish case, but a 111.85 P/E means future growth must continue to justify the market price. Investors focused on durable pharmaceutical franchises can view the KEYTRUDA and WINREVAIR results as the core evidence. More valuation-sensitive investors should treat the sharp one-day gain as a repricing event, not proof that every risk has disappeared.
MRK’s Earnings Repricing Has a Clear Investor Test
MRK rises today because Merck paired solid Q3 2026 results with strong KEYTRUDA execution, rapid WINREVAIR growth, constructive 2026 sales guidance, and supportive oncology data. The earnings catalyst is concrete, while the latest share-volume figure does not confirm above-average trading activity.
For investors, the central issue is whether Merck can keep converting pipeline progress into sales growth that supports its elevated valuation. The current quarter provides a credible foundation, but disciplined position sizing remains important after a 5.32% single-session move.
MRK is up because Merck reported strong third-quarter 2026 results, including $18.1 billion in sales and $2.04 GAAP EPS, which topped market expectations. Investors also responded to KEYTRUDA growth, a sharp rise in WINREVAIR sales, and supportive oncology data from ESMO 2026.
+Should I buy MRK stock now?
The article supports a constructive long-term case, but it also shows MRK is trading at a rich valuation after the rally. Investors may want to buy only if they are comfortable paying for continued earnings growth and pipeline execution.
+What was the main catalyst for Merck's stock move?
The main catalyst was Merck’s third-quarter 2026 earnings release. Strong sales, solid EPS, and positive updates on its oncology pipeline gave investors a clear reason to reprice the stock higher.
+Is the MRK rally backed by heavy trading volume?
Not really. The stock moved higher on earnings, but the latest normalized volume reading was only 0.2x its 200-day average, so the move was not confirmed by above-average share turnover.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on MRK?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.